NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.
This capital infusion is significant for NanoViricides as it continues to advance its lead drug candidate, NV-387, a broad-spectrum antiviral based on host-mimetic nanomedicine technology. NV-387 has received Orphan Drug Designation (ODD) from the U.S. FDA Office of Orphan Products Development (OOPD), which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug is designed to target a wide range of respiratory viral illnesses, including Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles, and has shown high efficacy in lethal animal infection models.
The company's approach is unique in that its nanomedicine technology mimics host cells, making it difficult for viruses and their variants to develop resistance. This positions NV-387 as a potential first-line treatment for patients presenting with respiratory viral infections at the doctor's office. The proceeds from this offering will likely be used to support clinical trials, manufacturing, and regulatory activities required to bring the drug to market.
Investors should note that the offering is a registered direct offering, meaning the securities are sold directly to the investor without an underwriter, which can be a cost-effective way to raise capital. The terms, including the exercise price of the warrants, reflect current market conditions and the company's need for funding. For more details, the full press release is available at https://ibn.fm/Z8Etj.
The news underscores NanoViricides' commitment to addressing unmet medical needs in antiviral therapy, particularly as the world continues to face threats from emerging viral diseases. With the FDA's ODD, NV-387 has the potential to become a key player in the antiviral market. The company's progress will be closely watched by investors and the medical community alike.